Novacyt S.A. (AIM:NCYT)

Market Cap	27.34M
Revenue (ttm)	19.63M
Net Income (ttm)	-41.76M
Shares Out	n/a
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,631
Average Volume	82,938
Open	37.20
Previous Close	38.25
Day's Range	37.20 - 39.50
52-Week Range	36.00 - 137.00
Beta	n/a
RSI	38.72
Earnings Date	Apr 30, 2025

About Novacyt

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 237
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: NCYT

Financial Performance

In 2024, Novacyt's revenue was 19.63 million, an increase of 69.53% compared to the previous year's 11.58 million. Losses were -41.76 million, 47.6% more than in 2023.